

ANNOUNCEMENT ON CHANGE OF THE CHAIRMAN OF THE BOARD

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

1. Resignation of the Chairman

On 25 November 2024, the Board received a resignation letter from Ms. Zhang Mingrui (张铭芮) (“**Ms. Zhang**”), pursuant to which she gave notice of her resignation as both a Director and the Chairman of the Board, due to a change in work arrangements (the “**Resignation**”). Following the Resignation, Ms. Zhang no longer holds any position within the Company.

In accordance with the relevant provisions including the Company Law and the Articles of Association of the Company, the Resignation shall take effect from the date on which Ms. Zhang’s resignation letter has been served on the Board. The Resignation will not cause the number of directors on the Board to fall below the statutory minimum, nor will it impact the Company’s daily operations and production.

During her tenure as Chairman of the Board, Ms. Zhang led the Board in focusing on the Company’s “1+5” strategy, strengthening corporate governance, and driving transformation and optimisation. She also led the Company in focusing on the market, revitalising its brand, and fostering innovation. Ms. Zhang was dedicated to enhancing the Company’s brand strength, innovation capabilities, product excellence, and service quality. She spearheaded the formulation of the Company’s “Three Cores and Nine Wings” product strategy, which emphasises expanding and strengthening core flagship products. These efforts collectively propelled the Company onto a fast track of high-quality development. The Board extends its sincere gratitude to Ms. Zhang for her significant contributions to the Company.

2. Election of the New Chairman

In accordance with the relevant provisions of the Company Law, the Securities Law, and the Articles of Association of the Company, the Company convened its 9th Board meeting for the financial year ending 31 December 2024 (“**FY2024**”) via teleconference on 26 November 2024. Upon nomination by the Board and review by the Nomination Committee of the Company, the Board considered and approved the proposed election of Ms. Wang Lei (王磊) (“**Ms. Wang**”), an Executive Director of the Company, as Chairman of the Board, for a term of office lasting until the conclusion of the current Board’s term. In accordance with the Articles of Association of the Company, the Chairman of the Board shall be the legal representative of the Company. Accordingly, Ms. Wang will also assume the role of the Company’s legal representative.

Please refer to the separate announcement dated 26 November 2024 made by the Company in relation to the resolutions passed at the 9th Board meeting for FY2024 for further details on Ms. Wang's resume.

The Nomination Committee of the Company, upon review of Ms. Wang's resume, agreed with the proposed election of Ms. Wang as Chairman of the Board.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
26 November 2024